Skip to main content

Chimeric Antigen Receptors (CARs) for Advanced Therapies

Objective

Chimeric antigen receptors (CARs) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that act as recognition molecules like antibodies or T-cell receptors. In this respect, CARs are increasingly used for cellular therapy to redirect T-cells specifically towards killing of cancer cells. Recent success stories of cancer therapy with CAR modified T-cells have raised enormous scientific and public expectations to cure severely ill patients. However, there are still many obstacles to overcome for translation into clinics because the technology for GMP-compliant manufacture of genetically modified cellular products is extremely complex and expensive. Moreover, CAR therapy needs to be improved with respect to off-target activity, safety and potency. Consequently, the envisaged project is overall aiming at a particular technological breakthrough in cellular cancer therapy by delivering a comprehensive CARAT platform explicitly tailored for automated, easy-to-handle and cost-efficient manufacture of CAR-modified ATMP. Specifically, we aim:

(a) to implement unique next-generation cell processing tools like the CliniMACS Prodigy
(b) to develop advanced enabling technologies to obtain more effective and safer cellular products by improved gene delivery and innovative CARs design
(c) to assemble tools and technologies towards an integrated CARAT process for automated GMP-compliant manufacture of gene-modified T-cells
(d) to demonstrate proof-of-concept and regulatory compliance
(e) to disseminate broadly applicable, simplified CAR T-cell technologies

In summary, our vision is to overcome current hurdles for translation of cellular therapies and to elevate them to the next level of standard-of-care thus serving patients with so far incurable solid tumours and hematologic malignancies. Thereby, we will empower Europe to become a global leader in the development and commercialisation of CAR T-cell tools and technologies.

Call for proposal

H2020-PHC-2014-2015

See other projects for this call

Sub call

H2020-PHC-2015-two-stage

Coordinator

MILTENYI BIOTEC BV & CO KG
Net EU contribution
€ 171 913,75
Address
Friedrich Ebert Strasse 68
51429 Bergisch Gladbach
Germany

See on map

Region
Nordrhein-Westfalen Köln Rheinisch-Bergischer Kreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 171 913,75

Participants (8)

OSPEDALE SAN RAFFAELE SRL
Italy
Net EU contribution
€ 913 300,00
Address
Via Olgettina 60
20132 Milano

See on map

Region
Nord-Ovest Lombardia Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 913 300,00
BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL
Germany
Net EU contribution
€ 715 533,75
Address
Paul-ehrlich-strasse 51-59
63225 Langen

See on map

Region
Darmstadt Offenbach, Landkreis
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Other funding
€ 715 533,75
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Net EU contribution
€ 646 770,00
Address
Rue De Tolbiac 101
75654 Paris

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Other funding
€ 646 770,00
UNIVERSITY COLLEGE LONDON
United Kingdom
Net EU contribution
€ 660 398,75
Address
Gower Street
WC1E 6BT London

See on map

Region
London Inner London — West Camden and City of London
Activity type
Higher or Secondary Education Establishments
Other funding
€ 660 398,75
TRAKCEL LIMITED
United Kingdom
Net EU contribution
€ 422 750,00
Address
10/11 Raleigh Walk Brigantine Place
CF10 4LN Cardiff

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Wales East Wales Cardiff and Vale of Glamorgan
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 422 750,00
UNIVERSITAETSKLINIKUM FREIBURG
Germany
Net EU contribution
€ 718 580,00
Address
Hugstetter Strasse 49
79106 Freiburg

See on map

Region
Baden-Württemberg Freiburg Freiburg im Breisgau, Stadtkreis
Activity type
Higher or Secondary Education Establishments
Other funding
€ 718 580,00
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
Germany
Net EU contribution
€ 561 087,50
Address
Heinrich-hertz-allee 1
66386 St Ingbert

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Saarland Saarland Saarpfalz-Kreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 561 087,50
MILTENYI BIOTEC GMBH

Participation ended

Germany
Net EU contribution
€ 1 178 825,00
Address
Friedrich Ebert Strasse 68
51429 Bergish Gladbach
Region
Nordrhein-Westfalen Köln Rheinisch-Bergischer Kreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 1 178 825,00